CELL INTELLIGENCE · 肿瘤细胞治疗研究

儿童实体瘤的嵌合抗原受体（CAR）-T 细胞疗法：当前突破、困境与策略

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.

儿童实体瘤的生物工程细胞疗法：未满足需求与测量整合方法

Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.

免疫功能低下宿主中耐药革兰阴性感染的新型抗生素：从关键试验到高风险实践

Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice.

CAR-T 细胞治疗临床试验全景与发展趋势的全球多维分析

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.

CAR-T 细胞治疗在儿童、青少年和年轻成人癌症患者中的关键作用

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

肿瘤微环境中的 B7-H3：对儿童实体瘤 CAR-T 细胞治疗的意义

B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors.

2024 EBMT 活动报告：跨越 100 万例造血细胞移植和 20, 000 例 CAR-T，细胞治疗领域的里程碑

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

CAR-T 细胞用于儿童实体瘤：下一步该往哪里走？

CAR T-cells for pediatric solid tumors: where to go from here?

STRIvE-02：全身给药 B7-H3 CAR-T 细胞治疗复发/难治性实体瘤患者的首次人体 I 期研究

STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory S

B7-H3 CAR-T 细胞可耐受，并显示出有限的抗肿瘤活性，且无急性在靶、肿瘤外毒性。高水平的 CAR-T 细胞扩增可能是实现客观缓解所必需的，但未明确的宿主和肿瘤微环境因素似乎是关键（ClinicalTrials.gov 标识符：NCT04483778）。

CAR-T 与 CAR-NK 作为实体瘤细胞免疫治疗

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.